Literature DB >> 22133206

Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients.

Kristian Winther1, Mads Nybo, Birgitte Vind, Susanne Møller Pedersen, Kurt Højlund, Lars Melholt Rasmussen.   

Abstract

BACKGROUND: Phosphate homeostasis is connected to glucose metabolism and is influenced by insulin, but the role of fibroblast growth factor 23 (FGF23) is unknown in this relation. Therefore, the levels of FGF23 and phosphate were investigated during a euglycemic-hyperinsulinemic clamp in healthy and type 2 diabetic individuals.
METHODS: The study population consisted of ten type 2 diabetic patients, ten weight-matched glucose-tolerant obese subjects, and ten healthy lean subjects. All subjects underwent a 4-h euglycemic-hyperinsulinemic clamp using physiological hyperinsulinemia (40 mU/min per m(2)) to determine glucose disposal rates. Blood samples for measurement of serum FGF23 and insulin, plasma phosphate and glucose, and HbA(1c) were drawn before and after insulin infusion.
RESULTS: The three groups did not differ in baseline levels of serum FGF23. Insulin infusion increased serum FGF23 in the diabetic group (p = 0.009), but not in the other groups. The increase in serum FGF23 correlated strongly with increase in insulin levels in the diabetic group (r = 0.83; p = 0.003). In the overall group insulin infusion suppressed plasma phosphate concentrations (p = 0.006), but with no differences between the groups.
CONCLUSIONS: Physiological hyperinsulinemia is under euglycemic conditions followed by a significant increase in serum FGF23 concentrations in diabetic individuals, which correlated with change in insulin level. The interplay between insulin effects and FGF23 may be important for the understanding of phosphate metabolism in relation to type 2 diabetes and its vascular complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133206     DOI: 10.3109/00365513.2011.640407

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  9 in total

Review 1.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

Review 2.  The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.

Authors:  Maitane Izaguirre; María J Gil; Ignacio Monreal; Fabrizio Montecucco; Gema Frühbeck; Victoria Catalán
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

3.  Insulin suppresses the production of fibroblast growth factor 23 (FGF23).

Authors:  Ludmilla Bär; Martina Feger; Abul Fajol; Lars-Oliver Klotz; Shufei Zeng; Florian Lang; Berthold Hocher; Michael Föller
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-14       Impact factor: 11.205

Review 4.  The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.

Authors:  Peter S N Rowe
Journal:  Cell Biochem Funct       Date:  2012-05-09       Impact factor: 3.685

5.  High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.

Authors:  Ming-Hsien Tsai; Jyh-Gang Leu; Yu-Wei Fang; Hung-Hsiang Liou
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

6.  Favourable serum calcification propensity with intraperitoneal as compared with subcutaneous insulin administration in type 1 diabetes.

Authors:  Peter R van Dijk; Femke Waanders; Andreas Pasch; Susan J J Logtenberg; Titia Vriesendorp; Klaas H Groenier; Jan-Luuk Hillebrands; Nanno Kleefstra; Rijk O B Gans; Harry van Goor; Henk J G Bilo
Journal:  Ther Adv Endocrinol Metab       Date:  2020-03-03       Impact factor: 3.565

7.  Changes in Serum Intact Fibroblast Growth Factor 23 Concentrations From Midlife to Late Life and Their Predictors in the Community: The ARIC Study.

Authors:  Junichi Ishigami; Yasuyuki Honda; Amy B Karger; Josef Coresh; Elizabeth Selvin; Pamela L Lutsey; Kunihiro Matsushita
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2022-04-27

8.  Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations.

Authors:  José Manuel Fernández-Real; Josep Puig; Marta Serrano; Mónica Sabater; Antoni Rubió; José María Moreno-Navarrete; Marina Fontan; Roser Casamitjana; Gemma Xifra; Francisco José Ortega; Javier Salvador; Gema Frühbeck; Wifredo Ricart
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

9.  Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes.

Authors:  Xiang Hu; Xiaojing Ma; Yuqi Luo; Yiting Xu; Qin Xiong; Xiaoping Pan; Yuqian Bao; Weiping Jia
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.